Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Fall;10(3):219-29.
doi: 10.1111/j.1527-3458.2004.tb00023.x.

Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome

Michel Bourin  1 , Eric Dailly, Martine Hascöet
Affiliations
Review

Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome

Michel Bourin et al. CNS Drug Rev. 2004 Fall.

Abstract

Several studies have suggested that the antipsychotic compound, cyamemazine, possesses anxiolytic properties in humans. The original pharmacological profile of cyamemazine (D(2), 5-HT(2A), 5-HT(2C), and 5-HT(3) receptor antagonist), which was established by binding, microdialysis and behavioral studies, is consistent with these observations. In the light/dark exploration test, cyamemazine demonstrated anxiolytic-like activity by acute, but not chronic administration. By chronic administration, however, cyamemazine increased the time spent in the open arms of the elevated plus maze (EPM) test demonstrating anxiolytic-like activity. The discrepancy between the results obtained in these tests by acute and chronic administration, could be due to a combination of dopamine D(2) receptor antagonism with antagonism of the 5-HT(2C) and 5-HT(3) receptors. The action of cyamemazine on both the dopaminergic system and 5-HT(3) receptors could also explain the activity of cyamemazine in the management of alcohol withdrawal demonstrated in preclinical studies. This potential indication for cyamemazine and its activity in benzodiazepine withdrawal syndrome have recently been investigated in clinical trials and the results of these studies are presented in this review.

PubMed Disclaimer

References

    1. Alvarez‐Guerra M, D'Alché‐Birée F, Wolf WA, Vargas F, Dib M, Garay RP. 5‐HT3 and 5‐HT2C antagonist properties of cyamemazine: Significance for its clinical anxiolytic activity. Psychopharmacology 2000;147:412–417. - PubMed
    1. Alvarez‐Guerra M, Hameg A, Bayle F, Dib M, Garay RP. 5‐HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Eur J Pharmacol 2002;454:235–239. - PubMed
    1. Archambault JC, Théodore F, Minne P. Utilisation du Tercian en monothérapie dans l'alcoolisme chronique (àpropos de 78 observations). Actualités Psychiatriques 1986;10:118–121.
    1. Amt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63–101. - PubMed
    1. Balldin J, Berggren U, Lindstedt G, Sunder A. Further neuroendocrine evidence for reduced D2 dopamine receptor function in alcoholism. Drug Alcohol Depend 1993;32:159–162. - PubMed

MeSH terms